THE EFFECTIVENESS OF ORAL DEXAMETHASONE FOR ACUTE BRONCHIOLITIS: A MULTICENTER R

口服地塞米松治疗急性细支气管炎的疗效：多中心研究

• 批准号: 7376200
• 负责人: KATHLEEN C BROWN
• 金额: $ 1.19万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376200
• 关键词: EFFECTIVENESS; ORAL; DEXAMETHASONE; ACUTE; BRONCHIOLITIS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Bronchiolitis is the most common lower respiratory infection in infants, and the respiratory condition leading to the most hospital admissions in young children and is arguably the most common serious illness of childhood lacking evidence-based treatment. As many as 90% of children will be infected with the respiratory syncytial virus, the most common cause of bronchiolitis, during their first two years of life. Although many can be treated as outpatients, bronchiolitis admissions are increasing. The objective of this study is to assess the effectiveness of oral dexamethasone for acute moderate-to-severe outpatient bronchiolitis in a blinded, multicenter, randomized controlled trial. Outcomes assessed will include the need for hospital admission (primary outcome) and severity measured by respiratory scores, and duration of symptoms (secondary outcomes).

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。毛细支气管炎是婴儿最常见的下呼吸道感染，也是导致幼儿住院最多的呼吸道疾病，可以说是缺乏循证治疗的儿童最常见的严重疾病。多达90%的儿童在生命的头两年会感染呼吸道合胞病毒，这是细支气管炎的最常见原因。虽然许多人可以作为门诊治疗，毛细支气管炎的入院人数正在增加。本研究的目的是在一项盲法、多中心、随机对照试验中评估口服地塞米松治疗急性中重度门诊毛细支气管炎的有效性。评估的结局将包括住院的需要（主要结局）和通过呼吸评分测量的严重程度以及症状持续时间（次要结局）。